101
|
Desestret V, Brisset JC, Devillard E, Moucharaffie S, Tappaz M, Nataf S, Honnorat J, Nighoghossian N, Berthezène Y, Wiart M. CMR 2007: 1.01: Early stages investigation of USPIO-induced signal loss after focal cerebral ischemia in mice. CONTRAST MEDIA & MOLECULAR IMAGING 2007. [DOI: 10.1002/cmmi.156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
102
|
Legras-Lachuer C, Wierinckx A, Lamigeon C, Rey C, Croze S, Belin MF, Honnorat J, Lachuer J. ProfileXpert : plateforme de génomique au service de la recherche et de la clinique. Ing Rech Biomed 2007. [DOI: 10.1016/j.rbmret.2007.11.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
103
|
Moucharrafie S, Wiart M, Cho TH, Leston J, Honnorat J, Nighoghossian N, Sindou M. Intérêts et limites des modèles d'ischémie cérébrale chez la souris (occlusion permanente par électrocoagulation vs occlusion transitoire par microfilament). Corrélation IRM haute résolution et histologie. Neurochirurgie 2007. [DOI: 10.1016/j.neuchi.2007.09.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
104
|
Knudsen A, Bredholt G, Storstein A, Oltedal L, Davanger S, Krossnes B, Honnorat J, Vedeler CA. Antibodies to CRMP3-4 associated with limbic encephalitis and thymoma. Clin Exp Immunol 2007; 149:16-22. [PMID: 17403058 PMCID: PMC1942032 DOI: 10.1111/j.1365-2249.2007.03379.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
We present a case with subacute limbic encephalitis (LE) and thymoma. Neither classical onconeural antibodies nor antibodies to voltage gated potassium channels (VGKC) were detected, but the serum was positive for anti-glutamic acid decarboxylase (GAD). The patient serum also stained synaptic boutons of pyramidal cells and nuclei of granule cells of rat hippocampus. The objective of the study was to identify new antibodies associated with LE. Screening a cDNA expression library identified collapsin response mediator protein 3 (CRMP3), a protein involved in neurite outgrowth. The serum also reacted with both CRMP3 and CRMP4 by Western blot. Similar binding pattern of hippocampal granule cells was obtained with the patient serum and rabbit anti-serum against CRMP1-4. The CRMP1-4 antibodies stained neuronal nuclei of a biopsy from the patient's temporal lobe, but CRMP1-4 expression in thymoma could only be detected by immunoblotting. Absorption studies with recombinant GAD failed to abolish the staining of the hippocampal granule cells. Our findings illustrate that CRMP3-4 antibodies can be associated with LE and thymoma. This has previously been associated with CRMP5.
Collapse
|
105
|
Azabou E, Derex L, Cakmak S, Honnorat J, Nighoghossian N, Trouillas P. G - 4 Infarctus tubéro-thalamique révélé par un ptôsis ipsilatéral. Rev Neurol (Paris) 2007. [DOI: 10.1016/s0035-3787(07)90510-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
106
|
Marignier R, Renoux C, Vukusic S, Sillevis Smitt P, Honnorat J, Confavreux C. H - 13 Ataxie cérébelleuse subaiguë liée à un auto-anticorps dirigé contre un récepteur au glutamate (mGluR1) : efficacité du traitement précoce ? Rev Neurol (Paris) 2007. [DOI: 10.1016/s0035-3787(07)90649-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
107
|
Ducray F, Honnorat J, Lachuer J. Principes et intérêts pour l’étude des maladies neurologiques et technologie des puces ADN. Rev Neurol (Paris) 2007; 163:409-20. [PMID: 17452943 DOI: 10.1016/s0035-3787(07)90417-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
INTRODUCTION DNA microarray is a powerful technology which can rapidly provide a high throughput and detailed view of the entire genome and transcriptome. In this review we discuss the basic principles behind gene expression microarrays, CGH arrays and DNA microarray genotyping, and their potential applications to neurological diseases. STATE OF THE ART Microarray gene expression profiling is a reliable technology that has already been used with great success in the molecular classification of cancer. It is a very promising technology in the field of Neurooncology. One of the interesting characteristics of DNA microarrays is also that they can be used in a non-hypothesis-driven manner to discover new genomic characteristics that will enable to establish new pathophysiological hypotheses. Such a strategy has already yielded interesting new insights in the study of multiple sclerosis, Alzheimer disease or neuromuscular diseases. With DNA microarray genotyping it is now possible to detect mutations in many genes simultaneously. CONCLUSIONS In Neurooncology DNA microarrays should help to establish a more accurate classification of brain tumors and recent studies have shown how gene expression profiling of brain tumors allows to uncover previously unrecognized patient subsets that differ in their survival. The applications of microarrays for the study of neurological diseases, like multiple sclerosis, Alzheimer disease or neuromuscular diseases are also promising both for generating new pathophysiological hypotheses and for enabling new molecular classifications. DNA microarray genotyping is a powerful technology that should help to discover genetic factors associated with multifactorial neurological disorders and help to diagnose complex neurogenetic diseases. This technology should also facilitate the realization of pharmacogenomic studies in neurological diseases.
Collapse
|
108
|
Jousserand G, Camdessanche JP, Honnorat J, Petiot P, Vial C, Antoine J. J - 17 Sensibilité des critères usuels pour le diagnostic de neuronopathie sensitive, chez 76 patients. Rev Neurol (Paris) 2007. [DOI: 10.1016/s0035-3787(07)90669-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
109
|
Launey M, Delmont E, Vénissac N, Honnorat J, Fredenrich A, Thyss A, Butori C, Vernin M, Lebrun C, Bozzolo E, Bourg V, Thomas P. H - 11 Encéphalite limbique paranéoplasique : cas rare d’une association anticorps antiRIDES et séminome médiastinal. Rev Neurol (Paris) 2007. [DOI: 10.1016/s0035-3787(07)90647-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
110
|
Abstract
Antibodies as diagnostic markers of ataxia
Collapse
|
111
|
Catenoix H, Honnorat J, Cartalat-Carel S, Chapuis F, Nighoghossian N, Trouillas P. Effets à long terme de la chimiothérapie chez 7 patients présentant un gliome de bas grade symptomatique. Rev Neurol (Paris) 2006; 162:1069-75. [PMID: 17086143 DOI: 10.1016/s0035-3787(06)75119-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
INTRODUCTION Whether aggressive treatment or no treatment is the optimal management for low-grade gliomas is controversial. However, symptomatic low-grade gliomas require prompt therapeutic intervention because of neurological impairment, uncontrolled seizures, and deterioration of life quality. METHODS We report the long-term follow-up, 71 months, of seven patients treated by procarbazine, lomustine and vincristine (PCV) therapy for a symptomatic low-grade oligodendrogliomatous tumor. The mean age at diagnosis was 47 years, the mean time from first symptoms to initiation of PCV therapy was 62 months (range 15-147). RESULTS All patients initially responded favorably, with improvement of the neurological symptoms and radiological response. Chemotherapy was clinically well tolerated, the main side effect being low hematological toxicity. During the follow-up, no progression was observed in two patients. For the five remaining patients, the time to progression after the PCV induction was 56+/-12 months (range 38 to 73). Four of these patients showed favorable response to a second line of treatment. CONCLUSION PCV therapy is an interesting therapeutic option for progressively symptomatic low-grade gliomas, even in cases with large tumoral volume. This treatment, of moderate toxicity, improves the quality of life and can result in long-term tumor stabilization.
Collapse
|
112
|
Mechtouff L, Hermier M, Nader B, Cartalat S, Derex L, Cakmak S, Honnorat J, Nighoghossian N. Stroke MRI may result in a therapeutic dilemma. Eur Neurol 2006; 56:235. [PMID: 17057384 DOI: 10.1159/000096492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2006] [Accepted: 07/17/2006] [Indexed: 11/19/2022]
|
113
|
Vedeler CA, Antoine JC, Giometto B, Graus F, Grisold W, Hart IK, Honnorat J, Sillevis Smitt PAE, Verschuuren JJGM, Voltz R. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol 2006; 13:682-90. [PMID: 16834698 DOI: 10.1111/j.1468-1331.2006.01266.x] [Citation(s) in RCA: 235] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Paraneoplastic neurological syndromes (PNS) are remote effects of cancer on the nervous system. An overview of the management of classical PNS, i.e. paraneoplastic limbic encephalitis, subacute sensory neuronopathy, paraneoplastic cerebellar degeneration, paraneoplastic opsoclonus-myoclonus, Lambert-Eaton myasthenic syndrome and paraneoplastic peripheral nerve hyperexcitability is given. Myasthenia gravis and paraproteinemic neuropathies are not included in this report. No evidence-based recommendations were possible, but good practice points were agreed by consensus. Urgent investigation is indicated, especially in central nervous system (CNS) syndromes, to allow tumour therapy to be started early and prevent progressive neuronal death and irreversible disability. Onconeural antibodies are of great importance in the investigation of PNS and can be used to focus tumour search. PDG-PET is useful if the initial radiological tumour screen is negative. Early detection and treatment of the tumour is the approach that seems to offer the greatest chance for PNS stabilization. Immune therapy usually has no or modest effect on the CNS syndromes, whereas such therapy is beneficial for PNS affecting the neuromuscular junction. Symptomatic therapy should be offered to all patients with PNS.
Collapse
|
114
|
Lladó A, Carpentier AF, Honnorat J, Sillevis-Smitt P, Twijnstra A, Blanco Y, Hart IK, Saiz A, Graus F. Hu-antibody-positive patients with or without cancer have similar clinical profiles. J Neurol Neurosurg Psychiatry 2006; 77:996-7. [PMID: 16844961 PMCID: PMC2077609 DOI: 10.1136/jnnp.2005.085753] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
115
|
Abstract
Paraneoplastic neurological syndromes (PNS) can be defined as remote effects of cancer that are not caused by the tumor and its metastasis or by infection, ischemia or metabolic disruptions. In most patients, the neurological disorder develops before the cancer becomes clinically overt and the patient is referred to the neurologist who has the charge of identifying a neurological disorder as paraneoplastic. They are usually severely disabling. PNS are rare and are seen in less than 1% of patients with cancer. PNS depend on an autoimmune process triggered by cancer and directed to antigens common to both the cancer and the nervous system designated as onconeural antigens. Because of their high specificity (>90%), the best way to diagnose neurological disorders as paraneoplastic is to identify one of the well-characterized onconeural antibodies in the patient's serum. In addition, as these antibodies are associated with a restricted range of cancer, they permit orientating the search of the underlying tumor at a stage where it is frequently not clinically overt. This is a critical point, as today the best way to stabilize PNS is probably to treat the cancer as soon as possible. Unfortunately, about one-third of the patients do not have detectable antibodies and 5-10% have an atypical antibody that is not well characterized.
Collapse
|
116
|
Cakmak S, Nighoghossian N, Desestret V, Hermier M, Cartalat-Carel S, Derex L, Honnorat J, Trouillas P. Pulmonary embolism: an unusual complication of cerebral venous thrombosis. Neurology 2006; 65:1136-7. [PMID: 16217078 DOI: 10.1212/01.wnl.0000178987.06734.54] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
117
|
|
118
|
Ducray F, Colin P, Cartalat-Carel S, Pelissou-Guyotat I, Mahla K, Audra P, Gaucherand P, Honnorat J, Trouillas P. Prise en charge des gliomes malins découverts au cours d’une grossesse. Rev Neurol (Paris) 2006; 162:322-9. [PMID: 16585887 DOI: 10.1016/s0035-3787(06)75018-4] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
INTRODUCTION Glioma is seldom diagnosed during pregnancy. In this situation management presents difficult problems for both neuro-oncologists and obstetricians. We report four cases and discuss the management of this unusual situation. CASE REPORT The first patient was admitted to hospital at 29 weeks' gestation because of a generalized seizure and a right hemiparesis. MRI showed a left fronto-insular lesion. A stereotactic biopsy was obtained and revealed an anaplastic oligodendroglioma. With corticosteroids the patient remained stable until cesarean delivery at 36 weeks. In post-partum additional treatment with chemotherapy was started. The second patient was hospitalized at 26 weeks' gestation because of cranial hypertension, right hemiparesis and aphasia. MRI showed an important left fronto-parietal lesion. Partial resection was performed at 28 weeks. Histology revealed a glioblastoma multiforme. With corticosteroids the patient remained stable until cesarean delivery at 33 weeks. In post-partum additional treatment with radiotherapy and chemotherapy was started. The third patient was admitted to the hospital at 12 weeks' gestation because of cranial hypertension. MRI showed a left frontal lesion. A subtotal resection was done at 13 weeks. Histology revealed a glioblastoma multiforme. Two weeks after surgery the patient's neurological condition worsened and in agreement with the patient a therapeutic abortion was decided. Afterwards additional treatment with radiotherapy and chemotherapy was started. The last patient received combined treatment with radiotherapy and chemotherapy for local recurrence of a mesencephalic high-grade glioma. A posteriori it was discovered that the patient was at 4 months' gestation during this treatment. Cesarean delivery was done at 36 weeks. The child was normal at birth and is still in good health 5 years later. CONCLUSION The management of gliomas diagnosed during pregnancy should not be different from the standard management of gliomas in young non-pregnant adults. Pregnant women because of their young age can have a long survival. Their pregnancy should not prevent them from receiving the best treatment for their glioma. Treatment will depend upon clinico-radiological presentation, histology, gestational age and the patient's desires. Generally speaking, surgical resection of high-grade gliomas should not be delayed during pregnancy. Progress in anesthesia and neurosurgery have greatly reduced the risks for the foetus. After delivery, if the delay between surgery and delivery is too long it is possible to begin cerebral radiotherapy during pregnancy. After the first trimester of gestation this treatment can be given without any important risks for the child.
Collapse
MESH Headings
- Abortion, Therapeutic
- Adrenal Cortex Hormones/therapeutic use
- Adult
- Algorithms
- Anesthesia, General
- Antineoplastic Agents/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Carbamazepine/therapeutic use
- Carmustine/administration & dosage
- Case Management
- Cesarean Section
- Chemotherapy, Adjuvant
- Cranial Irradiation
- Craniotomy
- Dacarbazine/analogs & derivatives
- Dacarbazine/therapeutic use
- Female
- Frontal Lobe
- Glioblastoma/drug therapy
- Glioblastoma/radiotherapy
- Glioblastoma/surgery
- Glioblastoma/therapy
- Humans
- Infant, Newborn
- Intracranial Hypertension/etiology
- Magnetic Resonance Imaging
- Male
- Neoplasm Recurrence, Local
- Nitrosourea Compounds/administration & dosage
- Nitrosourea Compounds/therapeutic use
- Organophosphorus Compounds/administration & dosage
- Organophosphorus Compounds/therapeutic use
- Paresis/drug therapy
- Paresis/etiology
- Prednisolone/therapeutic use
- Pregnancy
- Pregnancy Complications, Neoplastic/drug therapy
- Pregnancy Complications, Neoplastic/radiotherapy
- Pregnancy Complications, Neoplastic/surgery
- Pregnancy Complications, Neoplastic/therapy
- Prenatal Exposure Delayed Effects
- Radiotherapy, Adjuvant
- Remission Induction
- Supratentorial Neoplasms/drug therapy
- Supratentorial Neoplasms/radiotherapy
- Supratentorial Neoplasms/surgery
- Supratentorial Neoplasms/therapy
- Temozolomide
- Temporal Lobe
Collapse
|
119
|
Krolak-Salmon P, Androdias G, Meyronet D, Aguera M, Honnorat J, Vighetto A. Slow evolution of cerebellar degeneration and chorea in a man with anti-Yo antibodies. Eur J Neurol 2006; 13:307-8. [PMID: 16618353 DOI: 10.1111/j.1468-1331.2006.01152.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
120
|
Rollin N, Guyotat J, Streichenberger N, Honnorat J, Tran Minh VA, Cotton F. Clinical relevance of diffusion and perfusion magnetic resonance imaging in assessing intra-axial brain tumors. Neuroradiology 2006; 48:150-9. [PMID: 16470375 DOI: 10.1007/s00234-005-0030-7] [Citation(s) in RCA: 148] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2005] [Accepted: 09/22/2005] [Indexed: 11/29/2022]
Abstract
Advanced magnetic resonance (MR) imaging techniques provide physiologic information that complements the anatomic information available from conventional MR imaging. We evaluated the roles of diffusion and perfusion imaging for the assessment of grade and type of histologically proven intraaxial brain tumors. A total of 28 patients with intraaxial brain tumors underwent conventional MR imaging (T2- and T1-weighted sequences after gadobenate dimeglumine injection), diffusion imaging and T2*-weighted echo-planar perfusion imaging. Examinations were performed on 19 patients during initial diagnosis and on nine patients during follow-up therapy. Determinations of relative cerebral blood volume (rCBV) and apparent diffusion coefficient (ADC) were performed in the solid parts of each tumor, peritumoral region and contralateral white matter. For gliomas, rCBV values were greater in high-grade than in low-grade tumors (3.87+/-1.94 versus 1.30+/-0.42) at the time of initial diagnosis. rCBV values were increased in all recurrent tumors, except in one patient who presented with a combination of recurrent glioblastoma and massive radionecrosis on histology. Low-grade gliomas had low rCBV even in the presence of contrast medium enhancement. Differentiation between high- and low-grade gliomas was not possible using diffusion-weighted images and ADC values alone. In the peritumoral areas of untreated high-grade gliomas and metastases, the mean rCBV values were higher for high-grade gliomas (1.7+/-0.37) than for metastases (0.54+/-0.18) while the mean ADC values were higher for metastases. The rCBV values of four lymphomas were low and the signal intensity-time curves revealed a significant increase in signal intensity after the first pass of gadobenate dimeglumine. Diffusion and perfusion imaging, even with relatively short imaging and data processing times, provide important information for lesion characterization.
Collapse
|
121
|
Nataf F, Koziak M, Ricci AC, Varlet P, Devaux B, Beuvon F, Roujeau T, Page P, Cioloca C, Turak B, Schlienger M, Touboul E, Haie-Meder C, Vannetzel JM, Dhermain F, Honnorat J, Jouvet A, De Saint-Pierre G, Daumas-Duport C, Bret P, Roux FX. [Results of the Sainte-Anne - Lyons series of 318 oligodendroglioma in adults]. Neurochirurgie 2005; 51:329-51. [PMID: 16292177 DOI: 10.1016/s0028-3770(05)83494-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
INTRODUCTION Incidence of cerebral oligodendrogliomas is increasing because of better recognition made possible by improved classifications. We studied a homogeneous series using the Sainte-Anne grading scale in order to better understanding the history of these tumors with or without treatment and to assess prognosis and associated factors. PATIENTS AND METHODS A retrospective series of 318 adult patients with oligodendroglioma (OLG) treated at Hôpital Sainte-Anne, Paris (SA) and Hôpital Neurologique, Lyons (L) between 1984 and 2003 was analyzed: 182 grade A OLG (SA + L), 136 grade B among which a homogenous series of 98 (SA) were included. For grade A: age at diagnosis ranged from 21 to 70 (mean: 41), sex ratio was 1.28. For grade B: age at diagnosis ranged from 12 to 75 (mean: 45.5), sex-ratio was 1.58. The main first symptoms were: epilepsy (A: 91.5%; B: 76%), intracranial hypertension (A: 7.9%; B: 14.6%), neurological deficit (A: 5.1%; B: 17.7%). The most frequent locations were: frontal, insular and central for both A and B. Mean size was 55 mm for grade A, 62 mm for B. Calcifications were found in 20% of A, 48.5% of B. No tumor was enhanced on imaging (CT/MRI) in grade A, all but 7 in grade B. All patients underwent surgery either for biopsy (A: 47.2%; B: 53%), or removal which was partial (A: 26.4% vs B: 19.4%) or extended (A: 36.3% vs B: 37.8%). Fifty-six patients underwent 2 procedures and 12 three procedures. Radiotherapy was performed in 76.9% of grade A, and 91% of B patients, in the immediate postoperative period for 71% A and 82.7% B. Chemotherapy was delivered for 36% of grade A (in the event of transformation to grade B or failure of radiotherapy) and 67.5% of B patients. Among grade A tumors, 38% transformed into grade B within a mean delay of 51 months with a mean follow-up of 78 months. RESULTS Median survival was 136 months for grade A and 52 for grade B. Survival at 5, 10 and 15 was 75.5%, 51% and 22.4% for grade A vs 45.2%, 31.3% and 0% for grade B respectively. In univariate and multivariate analysis, grade A survival was associated with age at diagnosis, tumor size, large removal and response to radiotherapy. Grade B survival was associated with age at diagnosis, wide removal and sharply defined limits of the tumor on imaging. CONCLUSIONS Analysis of both published data and this series underlines many prognostic parameters. It shows that OLG are heterogeneous tumors even in each grade (A and B). Treatment should consequently progress towards more targeted procedures for patients mainly with postoperative radiotherapy and chemotherapy.
Collapse
|
122
|
Caudie C, Bancel J, Dupont M, Matanza D, Poitevin F, Honnorat J. [CSF levels and diagnostic utility of cerebrospinal fluid beta2-microglobulin]. Ann Biol Clin (Paris) 2005; 63:631-7. [PMID: 16330382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2005] [Accepted: 09/14/2005] [Indexed: 05/05/2023]
Abstract
CSF levels of beta2-microglobulin reflect immune activation and lymphoid cell turnover in CNS. There were proposed as a reliable marker of lymphoproliferative disorders in central nervous system in viral infections, inflammatory diseases, autoimmune diseases and malignancies. The aims of this study were to measure beta2-microglobulin on the automate Vidas of bioMérieux in 122 paired CSF and serum from control patients. We evaluated whether or not the elevated levels beta2-microglobulin in CSF can be a useful marker for diagnosis of lymphoproliferative disorders in 108 patients with neurological diseases. The concentrations of beta2-microglobulin in the CSF and sera from control patients were respectively 1.3 +/- 0.5 mg/L and 2 +/- 0.6 mg/L. The normal CSF to serum beta2-microglobulin ratio was 0.6 +/- 0.19. A CSF to serum beta2-microglobulin ratio greater than 1 was closely associated with intrathecal synthesis beta2-microglobulin in CNS lymphoproliferative disorders. Elevation of CSF beta2-microglobulin ratio is a sensitive marker of central nervous system disease activity by infiltrating lymphocytes in intracranial lymphomas (10/10) and paraneoplastic neurological syndromes (2/3).
Collapse
|
123
|
Mouton S, Nighoghossian N, Berruyer M, Derex L, Philippeau F, Cakmak S, Honnorat J, Hermier M, Trouillas P. Hyperthyroidism and Cerebral Venous Thrombosis. Eur Neurol 2005; 54:78-80. [PMID: 16118502 DOI: 10.1159/000087717] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2005] [Accepted: 06/29/2005] [Indexed: 11/19/2022]
Abstract
The demonstration of an underlying prothrombotic condition in cerebral venous thrombosis (CVT) may have important practical consequences in terms of prevention. Thyrotoxicosis through a hypercoagulable state may be a predisposing factor for CVT. The authors present the cases of 4 patients who developed CVT and hyperthyroidism. At the acute stage, hyperthyroidism was associated with an increase in factor VIII (FVIII). At follow-up, FVIII level remained increased in 2 patients. Hyperthyroidism may have an impact on FVIII level. Accordingly in patients with hyperthyroidism and neurological symptoms, the diagnosis of CVT should be considered and an exhaustive coagulation screening may be appropriate.
Collapse
|
124
|
Cartalat-Carel S, Chinot O, Honnorat J. Place de la chimiothérapie et de la radiothérapie dans le traitement des oligodendrogliomes. Neurochirurgie 2005; 51:379-92. [PMID: 16292180 DOI: 10.1016/s0028-3770(05)83497-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Twenty years ago, the discovery of the chemosensitivity of anaplastic oligodendrogliomas considerably boosted interest for these tumors. In spite of difficulties for histological diagnosis, numerous studies on radiotherapy and chemotherapy for oligodendrogliomas appeared these last years. They allowed to detail the appropriate role for these therapeutics. For low grade oligodendrogliomas, radiotherapy delays the anaplastic transformation, but does not modify the overall survival; its indication has to be discussed particularly in the absence of clinical symptoms. Chemotherapy seems to be effective for low grade oligodendrogliomas as well as anaplastic tumors. However, phase III studies are necessary to clarify the contribution of chemotherapy for the treatment of low grade oligodendrogliomas, mainly in relation to radiotherapy. In anaplastic oligodendrogliomas, in spite of the lack of phase III studies, radiotherapy seems to be effective. Chemotherapy is clearly effective, but the most appropriate timing (neoadjuvant, adjuvant, at recurrence) is unknown. Results of current prospective studies are awaited. Recently, molecular genetic analysis, particularly the loss of 1p and 19q chromosomes appears to demonstrate a genetic influence on both prognosis and response to treatment.
Collapse
|
125
|
Cartalat-Carel S, Camdessanché JP, Antoine JC, Honnorat J. Syndromes neurologiques paranéoplasiques. ACTA ACUST UNITED AC 2005. [DOI: 10.1016/j.emcn.2004.09.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|